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ABSTRACT
Objective: Assess the effect of abatacept on progression
of structural damage over 2 years in patients with
rheumatoid arthritis who had an inadequate response to
methotrexate.
Methods: 539 patients entered an open-label extension
of the AIM (Abatacept in Inadequate responders to
Methotrexate) trial and received abatacept. Radiographic
assessment of the hands and feet was performed at
baseline, year 1 and year 2. At year 2, each patient’s
radiographs were scored for progression blinded to
sequence and treatment allocation.
Results: In patients treated with abatacept for 2 years,
greater reduction in progression of structural damage was
observed in year 2 than in year 1. The mean change in
total Genant-modified Sharp scores was reduced from
1.07 units in year 1 to 0.46 units in year 2. Similar
reductions were observed in erosion and joint space
narrowing scores. Following 2 years of treatment with
abatacept, 50% of patients had no progression of
structural damage as defined by a change in the total
score of (0 compared with baseline. 56% of patients
treated with abatacept had no progression during the first
year compared with 45% of patients treated with placebo.
In their second year of treatment with abatacept, more
patients had no progression than in the first year (66% vs
56%).
Conclusions: Abatacept has a sustained effect that
inhibits progression of structural damage. Furthermore,
the mean change in radiographic progression in patients
treated with abatacept for 2 years was significantly lower
in year 2 versus year 1, suggesting that abatacept may
have an increasing disease-modifying effect on structural
damage over time.
Rheumatoid arthritis (RA) is a chronic autoim-
mune disease that usually leads to synovial joint
damage and consequent disability. Activated T
cells play a crucial part in the immunopathology of
RA.
1 T cell proliferation and interaction with other
cell types, including synovial macrophages, fibro-
blasts and B cells, result in the production of
proinflammatory cytokines and matrix metallo-
proteinases that promote synovitis and erosive loss
of subchondral bone. Thus, targeting T cell
activation is a rational therapeutic approach for
the treatment of RA.
T cell activation requires antigen recognition by
the T cell receptor, referred to as signal 1, as well as
a co-stimulatory signal, referred to as signal 2.
2
One of the best characterised co-stimulatory path-
ways involves the interaction of CD28 expressed
on T cells with CD80 and CD86 expressed on
antigen-presenting cells. Endogenous down-regula-
tion of CD28-mediated T cell co-stimulation occurs
through T cell expression of cytotoxic T lymphocyte
antigen 4 (CTLA-4). CTLA-4 binds to CD80 and
CD86 with higher avidity than CD28, thus prevent-
ing co-stimulation through this pathway, and is a
major down-regulatory signal for T cells.
Abatacept is a soluble, recombinant, fully
human fusion protein composed of the extracel-
lular domain of human CTLA-4 and the Fc domain
of human IgG1, which has been modified to
prevent complement fixation. Abatacept is the
first in a class of biological agents that target the
second signal required for full T cell activation, a
mechanism of action that is fundamentally differ-
ent than any other current biological RA therapy.
The efficacy of abatacept monotherapy has been
shown in a phase IIa trial in patients with RA with
an inadequate response to disease-modifying anti-
rheumatic drugs (DMARDs).
3 The efficacy of
abatacept added to methotrexate (MTX) was
demonstrated in the phase IIb and phase III trials
of patients with an inadequate response to MTX or
tumour necrosis factor-targeting agents.
4–6
Results from the 1-year phase III, randomised,
double-blind trial of Abatacept in Inadequate
responders to Methotrexate (AIM) trial have been
previously reported.
5 Abatacept added to MTX
therapy resulted in clinically significant improve-
ments in the signs and symptoms of RA, physical
function and health-related quality of life in
patients with an inadequate response to MTX.
Further, abatacept resulted in a statistically sig-
nificant slowing of the progression of structural
damage after 12 months of treatment.
Progressive structural damage is associated with
increasing disability over time.
78Thus, the effects
of abatacept treatment on radiographic outcomes
were assessed over longer-term treatment. Here we
present radiographic assessments after 2 years of
abatacept treatment in an open-label extension of
the AIM trial. These data demonstrate that radio-
graphic progression is significantly inhibited over
the 2 years. The maintenance of efficacy of
abatacept therapy on other clinical end points will
be described in full in another report.
PATIENTS AND METHODS
The study design, baseline characteristics and
results of the 12-month double-blind phase of this
trial have been reported previously.
5 Institutional
review boards or independent ethics committees
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the study protocol was provided by each patient.
Patients
Patients eligible to participate in the AIM trial were at least
18 years of age, met the American Rheumatism Association
criteria for RA,
9 and had RA for at least 12 months. All patients
were screened for tuberculosis. At randomisation, all patients
had persistent, active RA despite treatment with MTX, with
>10 swollen joints, >12 tender joints and a C-reactive protein
concentration of >1.0 mg/dl. Patients were required to have
received MTX therapy at a minimum dose of 15 mg/week for at
least 3 months, with the dose having been stable for a
minimum of 28 days prior to randomisation. A 28-day washout
period was required for all other DMARDs. Reduction of MTX
dosage in the first 6 months was permitted only in cases of
toxicity. Stable dosages of nonsteroidal anti-inflammatory
drugs or corticosteroids at (10 mg prednisone/day were
allowed, with a stable dosage for 25 days prior to randomisa-
tion. Adjustment of MTX and/or corticosteroid dosages were
permitted after month 6, as was treatment with an additional
DMARD if deemed appropriate by the investigator, including
hydroxychloroquine, sulfasalazine, gold or azathioprine.
Study protocol
During the first year, patients were randomised to receive a
fixed dose of abatacept of approximately 10 mg/kg body weight
or placebo in a 2:1 ratio. The dose of abatacept was 500 mg for
patients weighing less than 60 kg, 750 mg for patients weighing
60–100 kg, and 1 g for patients weighing more than 100 kg.
Study medication was infused intravenously over 30 min on
days 1, 15 and 29, and every 28 days subsequently. Patients
completing the double-blind period were eligible to enter an
open-label, long-term extension and receive abatacept therapy
every 28 days at a dose of approximately 10 mg/kg, as described
above. The loading dose used in the double-blind period was not
utilised here. No premedication was required for the intrave-
nous infusions.
Radiographic evaluation
Radiographic assessments of hands, wrists and feet were
performed at baseline, year 1 and year 2, or upon early
termination. The trial was powered for radiographic findings
at year 1, and the primary end point was the change in erosion
score, with secondary assessments of joint space narrowing
(JSN) and total score using the Genant-modified Sharp scoring
system.
5 For each patient, baseline, year 1 and year 2 radio-
graphs were all re-read at year 2 by two independent expert
readers blinded to the original treatment allocation and the
sequence of films.
10
The Genant-modified Sharp scoring system (fig 1) assesses
changes in structural damage, assigning scores for erosions of 0–
3.5 (eight gradations) for 14 sites in each hand and wrist, and six
sites in each foot.
11 12 JSN scores of 0–4 (nine gradations) are
assigned to 13 sites in each hand and six sites in each foot.
12 The
erosion and JSN scores are normalised to 145 for a maximum
total Genant-modified Sharp score of 290.
12 Inter-reader, intra-
class correlation coefficient (ICC) was determined based on the
baseline and year 1 readings.
10 Smallest detectable difference




The study was powered for change from baseline in the Genant-
modified Sharp erosion score and used a rank-based analysis of
covariance to compare changes between treatment groups at
year 1. The radiographic analyses were performed on a modified
intent-to-treat population at year 2. The modified intent-to-
treat population included patients who were randomised and
treated, completed the 1-year double-blind period, and con-
tinued to receive at least one dose of study medication during
the open-label period. Patients who discontinued abatacept
treatment during the open-label period were requested to return
for follow-up radiography at year 2, regardless of any
subsequent new anti-rheumatic therapy prescribed by the
investigator. Radiographs were taken at the time of disconti-
nuation in patients who were unwilling or unable to return at
year 2. In these patients, 2-year data were imputed using linear
extrapolation of the scores of the discontinuation film.
The changes from baseline in total Genant-modified Sharp
scores, erosion scores and JSN scores were charted as cumulative
probability plots to visually represent the distribution of all
radiographic data. The observed cumulative proportion (scores
ranked from the lowest to the highest and presented as a
cumulative proportion of all scores) was plotted against the
actual change from baseline of each score. The proportion of
observations that fall below each possible change from baseline
(y-axis) can be read on the x-axis.
14
RESULTS
Patients and study completion
Of the 652 patients randomised and treated in the double-blind
portion of the AIM trial, 433 received abatacept and 219
received placebo (table 1). As previously reported, baseline
demographics and clinical characteristics did not differ signifi-
cantly between patients in the abatacept and placebo groups.
5
After the 12-month double-blind treatment period, all patients
were eligible to receive open-label treatment with abatacept.
More patients receiving abatacept treatment (89%) completed
the 1-year double-blind phase relative to the placebo group
(74%). Of the 547 patients who completed 12 months of
treatment, 539 (83% of all randomised and treated patients)
were treated with abatacept in the open-label period (378
initially randomised to abatacept (87%) and 161 to placebo
(73.5%)). A high retention rate was maintained with open-label
abatacept treatment, with 90% of the patients who entered the
long-term extension completing 2 years.
Two-year radiographic data were available from 87% of
patients who entered the open-label period, which comprises
72% of all randomised and treated patients (467 of 652 patients;
table 1). Observed data were available for 97% of patients who
completed the open-label period; 454 of 467 patients had
radiographs at baseline and at year 2. Baseline and an early
termination film were available for the remaining 3% of
patients, and 2-year data were imputed by linear extrapolation.
The data include baseline and year 2 radiographs of 324 patients
treated with abatacept for 2 years (observed data in 315
patients, imputed data in nine patients). Therefore, the 2-year
data represent the majority of randomised patients. As
previously reported in an abstract,
10 a high degree of inter-
observer agreement was demonstrated by ICC for radiographic
assessments at baseline (0.90) and 12 months (0.92) and for
change between baseline and 12 months (0.82). The smallest
detectable differences were 3.5, 2.5 and 5.1, respectively, for
erosion, JSN and total score. These correspond to 1.9%, 1.3%
and 1.3%, respectively, of the maximum values for each of these
Extended report
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studies.
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Radiographic results: population-level data
The progression of structural damage was significantly reduced
in patients treated with abatacept over 2 years versus those
treated with placebo initially. Baseline erosion and JSN scores
were comparable in patients originally randomised to either
treatment group. Significantly lower mean changes in radio-
graphic progression were observed in patients treated with
abatacept for 2 years, with mean changes in total score, erosion
and JSN scores of 1.55, 0.84 and 0.71 units, respectively,
compared with 3.17, 1.48 and 1.69 units in patients treated with
placebo for 12 months prior to abatacept open-label therapy
(fig 2, table 2).
Patients treated with abatacept for 2 years also had lower
median changes in radiographic progression scores. The median
change from baseline in total Genant-modified Sharp scores was
0.0 units at year 1 and year 2 with abatacept treatment (fig 3),
versus median changes of 0.46 and 0.51 units at year 1 and year
2, respectively, in patients who received placebo prior to
abatacept therapy. Further, the median change in erosion score
was 0.0 units in patients treated with abatacept for 2 years,
compared with 0.26 units in patients originally in the placebo
group.
The mean change in the total score, erosion and JSN score
were lower from year 1 to year 2 (0.46, 0.21 and 0.24 units,
respectively) than the mean change in these scores from baseline
to year 1 (1.07, 0.62 and 0.45 units, respectively) in patients
treated with abatacept for up to 2 years (table 2). The
increasing effect of treatment was consistently observed for
both erosions and JSN.
Radiographic results: patient-level data
Radiographic results at 2 years demonstrate the maintenance of
effect of abatacept and MTX on non-progression of structural
damage in patients with no progression at year 1 (table 3),
defined as a change from baseline in total Sharp score of (0.
Overall, 50% of patients treated with abatacept did not progress
from baseline to 2 years of treatment (163 of 324 patients). At
2 years, non-progression in erosions and JSN (change (0) was
observed from baseline in 56% and 68% of these patients,
respectively. In patients treated with abatacept with no
radiographic progression at year 1, 79% had no radiographic
progression at year 2. Non-progression in erosions and JSN was
maintained at 2 years in 83% and 87% of patients with no
progression at 12 months.
Non-progression at year 2 was also achieved in patients with
initial damage progression on abatacept therapy. Of patients
treated with abatacept who demonstrated radiographic progres-
sion at year 1, 45% had no progression of structural damage at
year 2 (64 of 142 patients). Further, 53% of patients originally
randomised to placebo with progression at year 1 did not
progress at year 2 after receiving abatacept treatment (42 of 79
patients).
Cumulative probability plots showing the distribution of
change from baseline in total Genant-modified Sharp scores for
year 1 and year 2 are shown in fig 3. Comparison of the curves
in patients treated in the abatacept group (solid line) versus
Figure 1 Genant-modified Sharp scoring
system. Coloured areas indicate sites
used to evaluate erosion and joint space
narrowing (JSN) scores. Each site was
evaluated in 0.5-unit increments as
indicated. Erosion and JSN scores are
normalised to 145 for a maximum total
score of 290.






Subjects included in analyses
Day 365 328 (87.2) 144 (90.0)
Baseline and day 365 328 (87.2) 144 (90.0)
Day 729 324 (86.2) 143 (89.4)
Baseline and day 729 315 (83.8) 139 (86.9)
Imputation on day 729* 9 (2.4) 4 (2.5)
Subjects not included in the analyses
No day 365 value{ 2 (0.5) 1 (0.6)
No day 729 value{ 6 (1.6) 2 (1.3)
*Subjects are discontinued and qualified for imputation requirement. {Two subjects in
the abatacept group had evaluative radiographic assessment outside the pre-specified
visit window of day 365, and one subject in the placebo group had no radiographic
assessment on day 365. {Subjects had evaluative radiographic assessment outside
the pre-specified visit window of day 729.
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strates that abatacept treatment is associated with results in
decreased numbers of patients with progression of structural
damage. Furthermore, the amount of structural damage in
patients who progressed is lower in patients treated with
abatacept for both year 1 and year 2.
DISCUSSION
Abatacept has been shown to significantly reduce disease
activity in patients with RA. The previously described
randomised, double-blind, placebo-controlled portion of the
phase III study of abatacept in patients with RA with an
inadequate response to MTX demonstrated statistically sig-
nificant improvement in the signs and symptoms of disease,
physical function assessed by the health-assessment question-
naire disability index, and health-related quality of life.
5 In
addition, abatacept positively impacted the rate of structural
damage progression at 12 months, reducing it by approximately
50% compared with placebo. This placebo-controlled radio-
graphic finding from randomised clinical trials provides an
assessment of short-term effects on structural damage.
However, only long-term radiographic progression has been
associated with physical disability.
8 Therefore, it is important to
Figure 2 Mean change from baseline in total (A), erosion (B) and joint
space narrowing (C) Genant-modified Sharp scores for patients at
12 months and 2 years. *Placebo patients were switched to abatacept
after 12 months. All patients received background methotrexate.




year 2 D Year 1 to year 2
Total score
Abatacept 1.07 1.55 0.46
Placebo/abatacept 2.40 3.17 0.75
Erosion score
Abatacept 0.62 0.84 0.21
Placebo/abatacept 1.44 1.69 0.25
Joint space narrowing score
Abatacept 0.45 0.71 0.24
Placebo/abatacept 0.95 1.48 0.50
Baseline is day 1 of study. All randomised and treated patients who entered the open-
label period and had radiographs at baseline and year 1. Baseline and year 1
radiographs were re-read at day 729. Placebo patients were switched to abatacept in
the long-term extension (year 2). All patients received background methotrexate.
Figure 3 Cumulative probability distribution of changes from baseline
in Genant-modified total Sharp scores by treatment at year 1 (A) and
year 2 (B). The solid line represents patients treated with abatacept (A,B)
and the dotted line represents patients treated with placebo (A) or
treated with placebo for 12 months then abatacept for 12 months (B).
All patients received background methotrexate.
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of therapy.
The retention rate of patients receiving abatacept treatment
was high, with 89% completing the 1-year double-blind portion
of the AIM trial,
5 and 90% of the patients entering the long-
term extension completing year 2, suggesting the tolerability
and durability of response to abatacept. Further, radiographic
data were collected from a high percentage of patients, with 2-
year data available from 87% of patients entering the open-label
period, and observed data for 97% of patients; linear imputation
based on baseline and early termination films was used in only
3% of patients.
Of note, an increased proportion of patients randomised to
the placebo group withdrew from the double-blind portion of
the study (between baseline and year 1) due to lack of efficacy
(18% vs 3% in the abatacept group).
5 Patients initially
randomised to placebo who discontinued the study during the
double-blind period are not included in these calculations. As
these patients with worsening disease were not included in the
assessment of radiographic outcomes, the progression of
structural damage in patients initially randomised to placebo
may be underestimated. As is standard for the assessment
of radiographic outcome, readers were blinded to the sequence
of radiographs, thus eliminating bias for the expectation of
benefit.
Abatacept therapy resulted in inhibition of structural damage
progression over time. After 2 years of treatment, a significant
reduction in the progression of structural damage was observed
in patients treated with abatacept for 2 years relative to placebo
for 12 months plus abatacept for 12 months.
8 Lower mean
changes in total Genant-modified Sharp scores at both
12 months and year 2 were 1.07 vs 2.4 units, and 1.55 vs 3.17
units, respectively. Notably, abatacept had a clear benefit on
both the erosion and JSN scores.
The treatment effect for abatacept relative to placebo was an
approximately 50% reduction in mean progression of structural
damage in the first year of the study. The rate of progression of
structural damage when patients had received placebo treat-
ment for 2 years can be estimated by linear extrapolation from
the 12-month data of patients randomised to placebo. Patients
in the placebo group progressed .2 units in year 1 and can be
projected to progress 4–5 units over 2 years using linear
extrapolation. Overall, patients receiving abatacept treatment
for 2 years progressed approximately 1.5 units versus the
expected progression of approximately 4.5 units if placebo
treatment had been continued for the second year. Thus, the
effect of abatacept treatment in the second year of treatment
would hypothetically reduce radiographic progression by an
estimated two-thirds when compared with patients with
established disease receiving MTX alone.
Fewer abatacept-treated patients had progression of struc-
tural damage, and, overall, 50% of patients receiving abatacept
did not have radiographic progression over 2 years. In addition,
79% of patients treated with abatacept with no progression at
year 1 maintained no progression of structural damage at year 2,
demonstrating a durable effect on radiographic outcomes with
abatacept therapy. In addition, 45% of patients with some
progression at year 1 had no progression in year 2. As the
overwhelming number of patients entering the second year of
treatment completed the year, we are not reporting on a
selected group of responders.
The increasing effect of abatacept treatment on the progres-
sion of structural damage is consistent with other efficacy data;
the proportion of patients with American College of
Rheumatology (ACR) 50 and 70 responses were statistically
significantly increased from 6 months to 12 months in this
study.
5 The ACR 20, 50 and 70 responses; improvement in
physical function; and improvement in both the physical and
mental components of the Short-Form-36 health-related quality
of life scale in patients treated with abatacept for up to 3 years
will be described in full in a future report.
It is difficult to compare results across clinical trials with
other treatments that have described radiographic outcomes.
Confounding factors include the treatment and disease history
of each study population, differing rates of radiographic
progression for the control group in each trial, and the use of
different scoring systems for the measurement of radiographic
damage. The current study assessed the efficacy of abatacept in
patients with established RA and long duration of disease,
whereas several trials of other biological therapies, such as those
targeting tumour necrosis factor, involved patients with early
RA (eg, the ERA trial of etanercept
17 and the PREMIER trial of
adalimumab
18) or MTX-naive patients (the TEMPO trial of
etanercept
19). The Sharp-modified Sharp and the van der Heijde-
modified Sharp scoring systems utilised in the trials of tumour
necrosis factor-targeting agents,
16 17 20 as well as the Genant-
modified Sharp scoring system utilised here and in the
interleukin-1 receptor antagonist and rituximab studies,
18 21 all
have differences in joints assessed, scales applied and maximum
achievable scores. Thus, Sharp-, van der Heijde- and Genant-
modified Sharp scores cannot be directly inter-converted,
although they correlate moderately well cross-sectionally and
longitudinally. In addition, the definition of the progression of
structural damage varied among studies, including progression
defined as change >0 or the smallest detectable difference
among readers.
16–18 20 21 The Genant-modified scoring system
Table 3 Patients with no progression in structural damage measured by Genant-modified Sharp scores in
patients on abatacept therapy for 2 years
Percentage of patients with no progression
in structural damage*
Percentage of patients with no progression in
structural damage in year 2{
Outcome
Baseline to year 1
(n=328)
Baseline to year 2
(n=324)
Non-progressors at end
of year 1 remaining non-
progressors{
Progressors at end of
year 1 becoming non-
progressors
Erosion (%) 61 56 83 49
Joint space narrowing
(%)
74 68 87 52
Total (%) 56 50 79 45
All patients received background methotrexate.
*Defined by a change in the total score of (0 from baseline to year 1. {Defined by a change in the total score of (0 from year 1
to year 2.
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(0.90–0.92 cross-sectionally and 0.82 for change) and high
sensitivity to change (smallest detectable difference) for erosion
(3.5), JSN (2.5) and total score (5.1).
10
The inhibition of progression of structural damage with
abatacept has clinical implications for the prevention of
disability over time. The association of progression of structural
damage and impaired physical function over the long term has
been well correlated, and is strongest in established disease.
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Impacting the rate of joint destruction with continued
abatacept treatment is likely to impede progressive functional
disability, and thus may have increasing benefit for patients
over time. Further study in this and other patient populations
will assess the efficacy of abatacept therapy over longer periods
of time.
Funding: This study was funded by Bristol-Myers Squibb.
Competing interests: HG has been reimbursed by Bristol-Myers Squibb, Amgen,
Wyeth, Novartis, Merck, Sanofi-Aventis, Lilly, GSK, Roche and Genentech for speaking
fees and honoraria. HG has also received research funding from these organisations.
HG is a founder and share holder of Synarc, Inc., and serves as a member of the board
of directors. RW has been reimbursed .$10 000 by Bristol-Myers Squibb and
Schering-Plough for speaking fees and honoraria. J-CB is an employee of Bristol-Myers
Squibb, and has shares with the company. RA is an employee of Bristol-Myers Squibb,
and has shares with the company. GV is an employee of Bristol-Myers Squibb, and has
shares with the company. JT is an employee of Bristol-Myers Squibb, and has shares
with the company. JK has been reimbursed .$10 000 by Bristol-Myers Squibb for
speaking fees and honoraria. CP is an employee and shareholder of Synarc, Inc., and is
a provider of central image analysis, molecular marker assays and subject recruitment
for global clinical trials for numerous pharmaceutical and biotechnology companies
across a broad range of therapeutic areas.
REFERENCES
1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid
arthritis. N Engl J Med 2001;344:907–16.
2. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin
Rheumatol 2004;16:212–17.
3. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al.
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding,
double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-
five days after the first infusion. Arthritis Rheum 2002;46:1470–9.
4. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med 2005;353:1114–23.
5. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al.
Effects of abatacept in patients with methotrexate-resistant active rheumatoid
arthritis: a randomized trial. Ann Intern Med 2006;144:865–76.
6. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al.
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion
protein CTLA4Ig. N Engl J Med 2003;349:1907–15.
7. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K. The links
between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford)
2000;39:122–32.
8. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The
relationship between disease activity, joint destruction, and functional capacity over
the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009–17.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
10. Peterfy C, Miaux Y, Wu C, Jiang Y, Sieffert M, Mokliatchouk O, et al. High inter-
observer reproducibility of Genant-modified Sharp radiographic scoring of hands and
feet of patients with rheumatoid arthritis in the AIM (Abatacept in Inadequate
responders to Methotrexate). Ann Rheum Dis 2005;64(Suppl III):460.
11. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis.
Am J Med 1983;75:35–47.
12. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of
rheumatoid arthritis using a modified scoring method on digitized and original
radiographs. Arthritis Rheum 1998;41:1583–90.
13. Lassere M, Boers M, van der Heijde D, Boonen A, Edmonds J, Saudan A, Verhoeven
AC. Smallest detectable difference in radiological progression. J Rheumatol
1999;26:731–9.
14. Strand V, Landewe R, van der Heijde D. Using estimated yearly progression rates to
compare radiographic data across recent randomised controlled trials in rheumatoid
arthritis. Ann Rheum Dis 2002;61(Suppl 2):ii64–6.
15. Sharp JT, Wolfe F, Lassere M, Boers M, Van Der Heijde D, Larsen A, et al. Variability
of precision in scoring radiographic abnormalities in rheumatoid arthritis by
experienced readers. J Rheumatol 2004;31:1062–72.
16. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a
randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
17. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al.
A comparison of etanercept and methotrexate in patients with early rheumatoid
arthritis. N Engl J Med 2000;343:1586–93.
18. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven
R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of
combination therapy with adalimumab plus methotrexate versus methotrexate alone
or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had
not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
19. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with
each treatment alone in patients with rheumatoid arthritis: double-blind randomised
controlled trial. Lancet 2004;363:675–81.
20. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy:
results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial
evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum
2006;54:2793–806.
21. Genant HK. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis
patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring
methods. Semin Arthritis Rheum 2001;30:26–32.
Extended report
Ann Rheum Dis 2008;67:1084–1089. doi:10.1136/ard.2007.085084 1089